Park K., Dalton J.T., Narayanan R., Barbieri C.E., Hancock M.L., Bostwick D.G., Steiner M.S., Rubin M.A.
Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014 32:3 (206-211)
High-grade prostatic intraepithelial neoplasia (HGPIN) is considered a precursor lesion of prostate cancer (PCa). The predictive value of ERG gene fusion in HGPIN for PCa was interrogated as a post hoc analysis in the context of a randomized clinical trial. The GTx Protocol G300104 randomly assigned 1,590 men with biopsy-diagnosed HGPIN to receive toremifene or placebo for 3 years or until a diagnosis of PCa was made on prostate biopsy. As part of this phase III clinical trial, a central pathologist evaluated biopsies of patients with isolated HGPIN at baseline and 12, 24, and 36 months of follow-up. ERG immunohistochemistry was performed on biopsies from 461 patients and evaluated for protein overexpression. ERG expression was detected in 11.1% of patients (51 of 461 patients) with isolated HGPIN…(ver más)